US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Realheart receives EUR 750,000 in second grant payment from the European Innovation Council

Västerås, Sweden, December 29, 2023 – Scandinavian Real Heart AB (publ) today announces that the company has received its second payment from the European Innovation Council (EIC) grant that was awarded in December 2021, aimed at supporting the development of the artificial heart Realheart TAH. The payment of EUR 750,000 equals 30% of the total grant sum of EUR 2.5 million.The company was awarded the grant within the framework of the European Innovation Council Accelerator program, which main purpose is to support the development of European innovations that have the potential to create new

Report from the extraordinary general meeting in Scandinavian Real Heart AB on November 24, 2023

Press release November 24th, 2023Scandinavian Real Heart AB (the "Company") has on November 24, 2023, held an extraordinary general meeting where mainly the following decisions were made. Determination of the number of board members. The meeting resolved to approve the nomination committee's proposal that the number of members of the board of directors shall consist of eight ordinary board members without deputies. Election of board members. The meeting resolved to approve the nomination committee's proposal to elect Magnus Öhman, Stuart McConchie and Giovanni Lauricella to the

Interim Report 230701-230930

Press Release November 16, 2023 Revenue and Result Scandinavian Real Heart AB is working with research and development and currently has no sales of any products. The income reported for the period consists mainly of foreign currency exchange gains. Research and development costs of Realheart® TAH were capitalized during Q3 with 4.2 MSEK. 1.9 MSEK for purchased services and other external costs and 2.3 MSEK for personnel. During the period, write-downs of capitalized costs for research and development were made by 0 MSEK. Other external costs of 8.9 MSEK includes cost for

Realheart provides an update on the development and commercialization of its artificial heart

Västerås, Sweden, November 13, 2023 – Scandinavian Real Heart AB (publ) today provides a strategy update on the development and commercialization of its artificial heart, the Realheart TAH, which in initial testing has been shown to induce 80% lower levels of hemolysis compared to today's market-dominant artificial heart.  This update is based on a thorough analysis conducted under the guidance of the company's Board of Directors, including the new adjunct board members. Realheart will increase its focus on the use of the product as a bridging treatment ahead of organ transplantation and now

Notice to Attend the Extraordinary General Meeting in Scandinavian Real Heart AB

Press Release November 8, 2023 The shareholders in Scandinavian Real Heart AB, reg. no. 556729–5588 (the "Company"), are hereby invited to the Annual General Meeting on Friday, 24 November 2023 at 10.00 at Best Western Plus Hotel Plaza, Kopparbergsvägen 10, 722 13 Västerås. Registration for the Meeting begins at 09:30.Right to participate in the Meeting, etc. Shareholders who wish to participate in the Meeting shall ·be recorded in the share register kept by Euroclear Sweden AB no later than Thursday, 16 November 2023, and ·notify the Company their intention to

Realheart has successfully established a novel test system to evaluate hemolysis of its total artificial heart

Västerås, November 1, 2023 – Scandinavian Real Heart AB (publ.) today announces that the company has successfully established a closed-loop preclinical test system that replicates the body’s circulatory system and enables more precise evaluations of hemolytic events. Initial test results show that the company’s artificial heart, Realheart TAH, induces 80% less hemolysis compared to the current market leader. The company will shortly start the evaluation of hemolytic events using a clinical version of the product.Measurements of hemoglobin released from red blood cells (plasma free

Giovanni Lauricella is adjuncted to Realheart’s board of directors

Västerås, October 30 2023 – Scandinavian Real Heart AB (publ.) has today decided to adjunct Giovanni Lauricella to the board of directors, after being informed that the nomination committee intends to propose him as a new member of the board of directors at the next general meeting. Giovanni Lauricella is a managing partner at Lifeblood Inc., specializing in recruitment and fund raising for medtech companies.Giovanni Lauricella has worked with over 500 startups worldwide and is currently member of several boards. He also organizes the conference Med-Tech World, which gathers around 3,000

Realheart selected for Business Sweden’s Catalyst programme

Press release 2023-09-01 Scandinavian Real Heart AB has been selected for Business Sweden's scale-up programme Catalyst, which aims to create international growth. In the program targeting Sweden’s most innovative and promising companies, participants receive a customized project plan for market entry valued at 250,000 SEK and opportunities to build network in the market, among investors and other experts.- Scandinavian Real Heart is one of Sweden’s most exciting and innovative medtech companies. With Scandinavian Real Heart, Sweden has the opportunity to develop into a leading Life

Stuart McConchie Appointed Adjunct Board Member to Realheart

Press release 2023-08-30 Scandinavian Real Heart AB has decided to adjunct Stuart McConchie to the board of directors, after the nomination committee informed that it intends to propose him as new board member at the next general meeting. Stuart McConchie has held top positions at global medical technology companies for 25 years, guiding companies from research phase to commercialization of products.McConchie has worked with several mechanical circulatory assist device companies, most recently as CEO of UK based Calon Cardio Technology, and previously U.S. Jarvik Heart and Australian

Interim Report 230401-230630

Press Release, August 24, 2023 Revenue and Result Scandinavian Real Heart is working with research and development and currently has no sales of any products. The income reported for the period consists mainly of foreign currenty exhance gains. Research and development costs of Realheart® TAH were capitalized during Q2 with 3.5 MSEK. 1.2 MSEK for purchased services and other external costs and 2.3 MSEK for personnel. During the period, write-downs of capitalized costs for research and development were made by 0 MSEK. The item other external costs of 2.9 MSEK consists of

Realheart’s CEO to Speak at China Heart Congress

Press Release August 23, 2023 Scandinavian Realheart’s CEO Ina Laura Perkins has been invited to speak at the China Heart Congress, which will be held in Beijing on September 1-3, 2023. Ina Laura Perkins will speak about the company’s total artificial heart that is being developed for patients with heart failure.The conference, which is one of the largest in cardiovascular disease in the Asia/Pacific region, is expected to gather over 8,000 participants. Ina Laura Perkins has been invited by one of China's leading heart surgeons, Mr. Shenshou Hu, President of Fuwai Hospital in Beijing.

Realheart to Present at Three Scientific Conferences in Europe

Press Release August 22, 2023  Realheart will be presenting its research results at three different scientific conferences in Europe over the next month – the ESAO in Bergamo, the BDW in Rostock and the EUMS in Paris – where many future customers and partners will also be attending. At ESAO, the company will highlight its experiences with animal-free methods and challenge the industry to take the step away from animals.The annual conference of the European Society for Artificial Organs , which this time takes place in Bergamo, Italy, between 29 August and 1

Magnus Öhman Appointed Adjunct Board Member to Realheart

Press Release August 10, 2023 The nomination committee in Scandinavian Real Heart AB proposes that Magnus Öhman is elected to the board at the next general meeting. Until then, he will be an adjunct to the board. Magnus Öhman has extensive experience from the medical technology industry, including as CEO of St. Jude Medical's Swedish subsidiary within Cardiac Rhythm Management.The Swedish subsidiary in Cardiac Rhythm Management (CRM) had at the end of Magnus Öhman's time as CEO over 620 employees, of which 200 in research and development, and sales of over SEK 5 billion, of which SEK 900

Realheart Announces Last day of Trading With BTU and First day of Trading With Warrants of Series TO2

Press Release, August 2, 2023 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY,  WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE FURTHER REGISTRATION OR ANY OTHER MEASURES. Scandinavian Real Heart AB (publ)’s (“Realheart” or the “Company”) rights issue, in which the subscription period ended on July 7, 2023, has now been

Realheart Performs a Directed Issue to EIC in Connection With the Completed Rights Issue

Press Release July 26, 2023 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE FURTHER REGISTRATION OR ANY OTHER MEASURES. Scandinavian Real Heart AB ("Realheart" or the "Company") announces that the Company's board of directors, based on the authorization from the annual

Realheart Performs a Directed Issue of Units to Underwriters in Connection With the Completed Rights Issue

Press Release July 26, 2023 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY,  WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE FURTHER REGISTRATION OR ANY OTHER MEASURES. Scandinavian Real Heart AB ("Realheart" or the "Company") announces that the Company's board, with the support of the authorization from the annual general

Scandinavian Real Heart AB announces outcome in the Company’s rights issue

Pressrelease, 2023-07-12 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY,  WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE FURTHER REGISTRATION OR ANY OTHER MEASURES. Scandinavian Real Heart AB (publ) ("Realheart" or the "Company") has completed the rights issue of units, consisting of shares and warrants of series TO2,

The Subscription Period in Realheart’s Rights Issue Ends Today

Press Release, July 7, 2023 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY,  WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE FURTHER REGISTRATION OR ANY OTHER MEASURES. Today, July 7, 2023, is the last day to subscribe for units in Scandinavian Real Heart AB (publ)’s (“Realheart” or the “Company”) rights issue, which was

Realheart Awarded Close to SEK 1 Million From Tillväxtverket and Region Västmanland

Press Release July 5, 2023 Following Almi's evaluation, Scandinavian Realheart AB has been granted business development support of a total of SEK 0.850 million. Realheart submitted a total of four applications, all of which have now been granted."That Realheart is able to supplement its funding with additional public funds is a sign of the strong interest of society in making our artificial heart a reality and bringing it to market. It is a product that could give many people around the world a new lease on life," said Realheart CEO Ina Laura Perkins. The current support is given to

The Subscription Period in Realheart’s Rights Issue Ends on Friday

Press Release July 4, 2023 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY,  WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE FURTHER REGISTRATION OR ANY OTHER MEASURES. On friday, July 7, 2023, the subscription period for Scandinavian Real Heart AB (publ)’s (“Realheart” or the “Company”) rights issue of units, which was

German Cardiac Surgeon Estimates That the Market for a Company That can Provide a Good Enough Artificial Heart is Huge

Press Release July 3, 2023 Leading German cardiac surgeon Professor Jan Schmitto estimates that the number of end stage heart failure patients in Germany with a population of 82 million, is around 40-60,000 per year. Although not all these patients may meet the criteria for a total artificial heart (TAH), the market for a company that can provide a good one is huge.Jan Schmitto is Professor of Cardiac Surgery in the Department of Cardiac, Thoracic, Transplant and Vascular Surgery at Hannover Medical School, Germany. He is head of the Mechanical Circulatory Support (MCS) program and of

Realheart Enters Into Collaboration With Sahlgrenska for Clinical Studies

Press Release July 3, 2023 Scandinavian Real Heart AB initiates a collaboration with Chief Physician and Professor Göran Dellgren at the Transplantation Center and Thorax Clinic at Sahlgrenska University Hospital. The collaboration is part of the preparations for the clinical studies on patients with the company's artificial heart, which is planned to start when everything is ready. The intention is that Sahlgrenska University Hospital will eventually participate in the clinical study.Several experimental and pre-clinical studies will be carried out within the framework of the

Realheart Gets Go-Ahead for International Trademark Protection

Press Release, 28 June 2023 Scandinavian Realheart AB’s trademark registration of Realheart has been approved in important international markets, in addition to the protection the trademark already enjoys in Sweden. The registration allows the company to develop the brand so that it exclusively supports the company's total artificial heart.“We are developing something completely different from what is available on the market today, which is why trademark protection is particularly important to us. It provides us good opportunity to both build and defend the value of our products,” says

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe